Clinical trials: Branch Atheromatous Disease
Branch Atheromatous Disease
Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
Branch atheromatous disease (BAD)-related stroke, characterized by subcortical single infarcts without severe stenosis of the large artery, but with a clear atherosclerotic mechanism, is now regarded as a separate stroke type.
- Trial name
- BRANT (NCT06037889)
- Testing
- Tirofiban, Aspirin tablet, Clopidogrel tablet
- Where
- 25 sites in China
- Volunteers
- 516 people
- Sponsor
- Peking Union Medical College Hospital
Cerebral Infarction, Disease
A Multi-center Prospective Study of Branch Atheromatous Disease in China
Branch atheromatous disease (BAD), is regarded as one of the important etiologies for acute isolated subcortical infarction, especially in Asian population.
- Conditions
- Cerebral Infarction, Disease, Magnetic Resonance Imaging
- Trial name
- NCT04973774
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking Union Medical College Hospital
Branch Atheromatous Disease, Cognitive
Cognitive Outcomes in BAD-related Stroke
Branch atheromatous disease (BAD) is a distinct subtype of ischemic stroke that is particularly prevalent among Chinese and other Asian populations.
- Conditions
- Branch Atheromatous Disease, Cognitive, Deterioration, Clinical
- Trial name
- NCT07761182
- Testing
- END exposure
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Branch Atheromatous Disease, Acute Ischemic Stroke
Early Identification and Diagnosis of BAD-related Stroke
Branch atheromatous disease (BAD)-related stroke is an important subtype of acute ischemic stroke involving penetrating arteries and is associated with early neurological deterioration.
- Conditions
- Branch Atheromatous Disease, Acute Ischemic Stroke, Cerebral Infarction
- Trial name
- SMART-BAD (NCT07693816)
- Testing
- Multisource clinical-imaging artificial intelligence diagnostic assessment
- Where
- 11 sites in China
- Volunteers
- 1,602 people
- Sponsor
- Peking Union Medical College Hospital
Acute Stroke, Dual Antiplatelet Therapy
Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
Branch atheromatous disease (BAD) has been reported to contribute to small-vessel occlusion and is associated with a higher possibility of early neurological deterioration (END).
- Conditions
- Acute Stroke, Dual Antiplatelet Therapy, Statin
- Trial name
- SATBRAD (NCT04824911)
- Testing
- Clopidogrel, Aspirin, Atorvastatin
- Where
- Taiwan
- Volunteers
- 376 people
- Sponsor
- Chang Gung Memorial Hospital
Stroke, Thrombolysis
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
Rationale and Relevance: Branch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and…
- Conditions
- Stroke, Thrombolysis, DAPT(Dual Antiplatelet Therapy), SAPT(Single Antiplatelet Therapy)
- Trial name
- NCT07299994
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 462 people
- Sponsor
- Sigmund Freud PrivatUniversitat
Branch Atheromatous Disease
Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction
Perforating artery territorial infarction (PAI) refers to a single ischemic lesion in a single perforating arterial territory and branch atheromatous disease (BAD) is an important type.
- Trial name
- STRATEGY (NCT05310968)
- Testing
- Tirofiban hydrochloride sodium chloride injection, Aspirin
- Where
- 37 sites in China
- Volunteers
- 970 people
- Sponsor
- Beijing Tiantan Hospital